Ser117

Site Information
ARKstRRsIRLPEtI SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451306

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 )
Relevant cell line - cell type - tissue:	'brain, embryonic' ( 12 , 25 , 26 ) , 'fat, brown' ( 5 ) , 3T3-L1 (fibroblast) ( 19 , 20 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , BaF3 ('B lymphocyte, precursor') ( 14 , 15 , 16 , 17 ) , brain ( 5 , 27 , 28 ) , heart ( 5 , 10 , 11 , 18 , 29 , 30 ) , liver ( 4 , 7 , 9 , 21 , 22 , 23 , 24 ) , liver [leptin (mouse), homozygous knockout] ( 4 ) , lung ( 5 ) , macrophage-bone marrow ( 6 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 6 ) , RAW 264.7 (macrophage) ( 2 ) , spleen ( 5 ) , stromal ( 3 )

In vivo Characterization

Methods used to characterize site in vivo:

mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 )

Relevant cell line - cell type - tissue:

'brain, embryonic' ( 12 , 25 , 26 ) , 'fat, brown' ( 5 ) , 3T3-L1 (fibroblast) ( 19 , 20 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , BaF3 ('B lymphocyte, precursor') ( 14 , 15 , 16 , 17 ) , brain ( 5 , 27 , 28 ) , heart ( 5 , 10 , 11 , 18 , 29 , 30 ) , liver ( 4 , 7 , 9 , 21 , 22 , 23 , 24 ) , liver [leptin (mouse), homozygous knockout] ( 4 ) , lung ( 5 ) , macrophage-bone marrow ( 6 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 6 ) , RAW 264.7 (macrophage) ( 2 ) , spleen ( 5 ) , stromal ( 3 )

Upstream Regulation
Treatments:	LPS ( 6 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 28852199 Curated Info
2	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
5	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
6	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
7	Guo A (2009) CST Curation Set: 7767; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
8	Guo A (2008) CST Curation Set: 4000; Year: 2008; Biosample/Treatment: cell line, E3 +/+/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
9	Possemato A (2008) CST Curation Set: 3856; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
10	Possemato A (2008) CST Curation Set: 3848; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
11	Possemato A (2008) CST Curation Set: 3850; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
12	Possemato A (2008) CST Curation Set: 3829; Year: 2008; Biosample/Treatment: tissue, brain, embryonic/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
13	Guo A (2007) CST Curation Set: 3464; Year: 2007; Biosample/Treatment: cell line, E6-rictor-/-/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
14	Gu T (2007) CST Curation Set: 3415; Year: 2007; Biosample/Treatment: cell line, BaF3/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
15	Gu T (2007) CST Curation Set: 3416; Year: 2007; Biosample/Treatment: cell line, BaF3/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
16	Gu T (2007) CST Curation Set: 3417; Year: 2007; Biosample/Treatment: cell line, BaF3/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
17	Gu T (2007) CST Curation Set: 3419; Year: 2007; Biosample/Treatment: cell line, BaF3/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
18	Guo A (2007) CST Curation Set: 3228; Year: 2007; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
19	Guo A (2007) CST Curation Set: 3216; Year: 2007; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
20	Guo A (2007) CST Curation Set: 3217; Year: 2007; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
21	Guo A (2007) CST Curation Set: 3211; Year: 2007; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
22	Guo A (2007) CST Curation Set: 3212; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
23	Guo A (2007) CST Curation Set: 3027; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
24	Guo A (2007) CST Curation Set: 3028; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
25	Guo A (2007) CST Curation Set: 3029; Year: 2007; Biosample/Treatment: tissue, brain, embryonic/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
26	Guo A (2007) CST Curation Set: 3030; Year: 2007; Biosample/Treatment: tissue, brain, embryonic/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
27	Guo A (2007) CST Curation Set: 3031; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
28	Guo A (2007) CST Curation Set: 3032; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
29	Guo A (2007) CST Curation Set: 3033; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info
30	Guo A (2007) CST Curation Set: 3034; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621 Curated Info